A study of effectiveness of Remimazolam in Modified Electroconvulsive Therapy

未提供0 个研究点目标入组 60 人开始时间: 待定最近更新: 2024年11月6日

试验速览

暂无简介。

•Patients admitted to the Mental Care Center Ward of Showa University Northern Yokohama Hospital and undergoing mECT
•Patients with ASA-PS2 and 3
•Persons who have obtained written consent to participate in this study from the individual or a surrogate
•Those who are judged to be eligible for participation in this study by the physician in charge of the study, etc. in the pre-test specified in the protocol of this study

•Patients with intracranial hypertension, cerebral aneurysm, recent myocardial infarction (within 3 months), angina pectoris, congestive heart failure
•Patients with bronchial asthma
•Patients with neuromuscular disease
•Patients with a history of hypersensitivity to remimazolam besilate, propofol itself or its components, acute angle closure glaucoma, myasthenia gravis, shock, coma, or acute alcohol intoxication with suppressed vital signs
•Patients within 3 months of participation in other clinical research
•Other patients who are judged by the investigator to be ineligible for this study.

4AT-J(Immediately after surgery)

未报告次要终点

发起方

未提供